Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Representative image of oncology researchers reviewing tumor imaging and clinical trial data, reflecting Immunome’s Phase 3 RINGSIDE results for varegacestat in adults with progressing desmoid tumors.
Pharma & Biotech

Why Immunome’s RINGSIDE data may reset expectations in desmoid tumor treatment

Discover how Immunome’s Phase 3 RINGSIDE data could reshape desmoid tumor treatment and gamma secretase inhibitor competition.

Read More
Representative image: An oncologist reviews lymphoma scan data in a clinical setting as Incyte’s tafasitamab combination shows improved progression-free survival in high-risk diffuse large B-cell lymphoma, raising new questions about the future of first-line DLBCL treatment.
Pharma & Biotech

Incyte’s frontMIND data put pressure on decades-old R-CHOP dominance in high-risk DLBCL

Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.

Read More
Representative image of oncology researchers studying tumor biology in a modern laboratory, reflecting Exelixis’ CABINET trial data on CABOMETYX and its potential role in advanced neuroendocrine tumor treatment.
Pharma & Biotech

Can Exelixis defend its oncology franchise with deeper CABINET evidence?

Read how Exelixis’ CABINET subgroup data could sharpen cabozantinib’s role in advanced neuroendocrine tumor care.

Read More
Representative image of an oncologist and clinical care team reviewing AI-powered cancer trial data, reflecting Massive Bio’s Reticulum Nexus push to improve oncology trial matching, biomarker reassessment and patient access after its ASCO 2026 product suite announcement.
Pharma & Biotech

How Massive Bio’s Reticulum Nexus suite is targeting the hidden bottlenecks in cancer trials

Can Massive Bio’s Reticulum Nexus suite close oncology trial access gaps? Find out how AI agents may reshape cancer trial navigation today!

Read More
Representative image of a hepatology researcher reviewing rare liver disease clinical data, reflecting Mirum Pharmaceuticals’ EASL 2026 updates on volixibat, brelovitug and maralixibat across PSC, HDV and PFIC programs.
Pharma & Biotech

Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?

Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.

Read More
Representative image of a clinical oncology research setting as PeproMene Bio’s PMB-CT01 BAFF-R CAR T data highlight a potential new treatment path for relapsed B-cell lymphoma after CD19 CAR T failure.
Pharma & Biotech

PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma

PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.

Read More
Representative image of oncology researchers reviewing colorectal cancer imaging and clinical trial data, reflecting how the KLEOS adaptive trial platform could support faster evaluation of new colorectal cancer therapies.
Pharma & Biotech

Can KLEOS change how colorectal cancer trials are run for patients with limited treatment options?

CRC trials need faster evidence. KLEOS could test more therapies under one platform. Read why the model matters.

Read More
Representative image of obesity treatment research. Kalohexis’ 710GO data highlights growing interest in dual MC3R and MC4R activation as the next frontier in weight loss drug development.
Pharma & Biotech

Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight

GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.

Read More
Representative image: An oncologist reviews lung scan and precision medicine data, reflecting how Rybrevant plus Lazcluze could reshape first-line treatment expectations for atypical EGFR-mutated non-small cell lung cancer.
Pharma & Biotech

Is atypical EGFR-mutated NSCLC becoming Johnson & Johnson’s next precision oncology battleground?

Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.

Read More
Representative image showing a modern breast cancer consultation as Menarini’s elacestrant and capivasertib data raise fresh questions about oral targeted therapy in metastatic disease.
Pharma & Biotech

Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations

Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?

Read More